Data from a total of 27 studies presented at ADA over 8 years reinforce Dario's strategic move closer to care, expanding revenue model into claims-based and outcomes-driven payments serving health pla
Expansion driven by highly successful partnership based on Dario's consistent ability to engage members and deliver scalable value across cardiometabolic conditions NEW YORK, May 26, 2026 /PRNewswire/
DarioHealth Corp. (DRIO) Q1 2026 Earnings Call Transcript

DarioHealth Q1 Earnings Call Highlights

11:06am, Wednesday, 13'th May 2026
DarioHealth NASDAQ: DRIO reported sequential revenue growth for the second straight quarter while outlining plans to expand its digital health platform further into care delivery, management said on t
DarioHealth Corp. (DRIO) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to a loss of $1.2 per share a year ago.
First quarter 2026 revenues increased to $5.6 million, marking the second consecutive quarter of sequential growth Operating expenses decreased by 21% year-over-year and decreased by 8% quarter-over-q
Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, May 4, 2026 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital
Findings highlight the role of continuous behavioral support in improving focus, productivity and day-to-day functioning – key priorities for employers and health plans Statistically significant imp
Mr. Palumbo's deep relationships across health systems, payers and healthcare's senior executive community expected to accelerate Dario's commercial partnerships and position the Company to realize it
DarioHealth (NASDAQ: DRIO - Get Free Report) and Thermo Fisher Scientific (NYSE: TMO - Get Free Report) are both medical companies, but which is the better investment? We will compare the two business

DarioHealth Q4 Earnings Call Highlights

01:02am, Saturday, 21'st Mar 2026
DarioHealth (NASDAQ: DRIO) executives highlighted record commercial momentum and continued cost reductions on the company's fourth-quarter and year-end 2025 earnings call, while also addressing the re
DarioHealth Corp. (DRIO) Q4 2025 Earnings Call Transcript
DarioHealth Corp. (DRIO) came out with a quarterly loss of $0.8 per share versus the Zacks Consensus Estimate of a loss of $1.57. This compares to earnings of $0.2 per share a year ago.
Fourth quarter 2025 revenues grew sequentially to $5.2 million as compared to $5.0 million in the third quarter of 2025 2025 full-year revenue was $22.4 million, compared to $27.0 million in 2024,
Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, March 11, 2026 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digit
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE